Drug intelligence / Profile preview

VisiDisc

Development stage: Unknown
Lead developer: Skye Biologics
Administration: Ophthalmic

Overview

VisiDisc is a dehydrated amniotic membrane allograft used in ophthalmology, primarily as a biological implant for ocular surface reconstruction and healing. It is processed from human amniotic tissue and designed to provide an ideal age-zero tissue implant, supporting wound healing, reducing inflammation, and minimizing scarring on the ocular surface. VisiDisc is available in both thin (amnion-only) and thick (chorion-based) configurations for improved handling and optimal coverage during surgical procedures. The product preserves the complete extracellular matrix using proprietary processing methods such as BioECM preserved by HydraTek[1][2]. Amniotic membrane allografts like VisiDisc are commonly used to treat various eye conditions requiring corneal or conjunctival repair[8].

Brand names: VisiDisc

Beyond the preview

Go deeper on VisiDisc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisiDisc.

Explore the full profile